Comparison of Safety and Efficacy of Coronary Drug-coated Balloon (DCB) Combined With Spot Stenting of Drug-eluting Stent (DES) Versus Second-generation DES for Treating Diffuse Coronary Artery Lesions: a Prospective, Randomized, Controlled Clinical Trial

Inclusion Criteria: * Patient-related * Patients who have typical angina pectoris symptoms with obvious evidence of ischemia; * Patients whose ages are between 18-80 years; * Patients who must agree to receive a 9-month angiographic follow-up; * Patients who must agree to receive clinical follow-up of 30 days, and 3, 6, 9, 12, 24 and 36 months; * Patients who can understand the purpose of this study both psychologically and linguistically, demonstrating sufficient compliance to the study protocol; * Patients who express their recognition of the risks and benefits described in the informed consent form by providing their inform consent; * Lesion-related * Diffuse coronary artery disease in situ; * Reference target vessel diameter of 2.5-4.0 mm and length of \> 25 mm; * Non-target vessel lesions needing to receive a successful intervention therapy first before randomization to receive treatment for target lesions (note: within the same hospitalization); * Visually estimated diameter stenosis of ≥70%, or diameter stenosis of ≥50% with objective evidences of ischemia (treadmill exercise testing, ECT or FFR\<0.8) Exclusion Criteria: * Patient-related: * Patients who have the attack of myocardial infarction within the past week, or whose troponin fails to return to normal although myocardial infarction has occurred for over one week; * Patients with serious congestive heart failure or NYHA IV-level serious heart failure; * Patients whose left ventricular ejection fraction is \< 30%; * Patients who have medical history of stroke or TIA within 6 months prior to the surgery; * Patients who have a current or previous history of serious liver failure and thereby fail to meet the requirements of angiography; * Patients who have a current or previous history of serious kidney failure (GFR\<30 ml/min) and thereby fail to meet the requirements of angiography; * Patients who have a previous history of intracranial neoplasms, aneurysm, arteriovenous malformation or cerebral hemorrhage; * Patients whose life expectancy does not exceed 1 year or who are difficult to follow up clinically; * Patients who have been scheduled to undergo elective surgery which may lead to the early discontinuation of ADP receptor antagonists; * Pregnant or lactating women or women who are planning to become pregnant during the study. * Patients participating in any other clinical trial; * Patients who are considered not suitable for inclusion by the investigator for any other reason; * Lesion-related: * Patients who have the evidence of extensive thrombosis in target vessels prior to the interventional therapy; * Patients who have left main coronary artery disease or graft lesions needing to be treated; * Patients who have bifurcation lesions with a side-branch vessel diameter of \>2.5 mm; * Patients who have lesions at the ostia of coronary artery, at the circumflex branch, at the ostia of anterior descending branch or within 5 mm at the ostia of coronary artery; * Severe intimal tear disease; * In-stent restenosis; * Lesions which can not be treated with PTCA or other intervention technologies; * Lesions with serious calcification; * Concomitant medication related * Patients who have a physique prone to hemorrhage and are prohibited from taking anticoagulants or antiplatelet drugs; * Patients who can not tolerate Aspirin and/or Clopidogrel, or who have serious hypohepatia and must not use Clopidogrel; * Patients who can not tolerate or have known allergy to heparin, contrast media, paclitaxel, iopromide, rapamycin, poly(lactic-co-glycolic acid) polymers or stainless steel, etc,; * Patients with a history of leukopenia (with WBC\<3×109/L for more than 3 days), neutropenia (with ANC \<1,000 cells/mm3 for more than 3 days), or thrombocytopenia (with platelet count \<100,000/mm3);